Inotuzumab ozogamicin, an ADC comprised of a humanized mAB against CD22 conjugated to the cytotoxic agent calicheamicin, led to a higher progression-free and overall survival in B-ALL patients compared to the standard therapy [58]. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.